Discovering interactions in augmentation strategies: Impact of duloxetine on the metabolism of aripiprazole
Basic & Clinical Pharmacology & Toxicology · 2023
DOI: 10.1111/bcpt.13875 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2023. Verfasst von Teresa Margraff und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital RWTH Aachen, Aachen, Germany. Hauptthemen laut MEDLINE: Antipsychotic Agents, Quinolones. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
Objective
We aimed to unravel potential pharmacokinetic interactions between aripiprazole and duloxetine.
Methods
Plasma concentrations of aripiprazole in two groups of 78 patients each, receiving aripiprazole as a monotherapy or combined with duloxetine, were compared. A potential impact of duloxetine on the metabolism of aripiprazole was expected in higher plasma concentrations of aripiprazole and higher dose‐adjusted plasma concentrations.
Results
Patients co‐medicated with duloxetine showed significantly higher plasma concentrations of aripiprazole by 54.2% ( p = 0.019). Dose‐adjusted plasma concentrations were 45.6% higher ( p = 0.001); 12.8% of these patients exhibited aripiprazole plasma concentrations above the upper limit of the therapeutic reference range, in the control group this was only the case for 10.3% of the patients. A positive relationship was found between the daily dose of duloxetine and dose‐adjusted plasma concentrations of aripiprazole ( p = 0.034). As dehydroaripiprazole concentrations were not available, conclusions for the active moiety (aripiprazole plus dehydroaripiprazole) could not be drawn.
Conclusions
Combining duloxetine and aripiprazole leads to significantly higher drug concentrations of aripiprazole, most likely via an inhibition of cytochrome P450 CYP2D6 and to a lesser extent of CYP3A4 by duloxetine. Clinicians have to consider increasing aripiprazole concentrations when adding duloxetine to a treatment regimen with aripiprazole.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital RWTH Aachen, Aachen, Germany.
- JARA-Translational Brain Medicine, RWTH Aachen University, Aachen, Germany.
- Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatry University Hospital Zurich, University of Zurich, Zurich, Switzerland.
- Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York, USA.
- Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York, USA.
- Department of Psychiatry and Psychotherapy, Clinical Pharmacology, University of Regensburg, Regensburg, Germany.
ORCID-Profile: Georgios Schoretsanitis, Arnim Johannes Gaebler, Michael Paulzen
Zitieren
APA
Margraff, T., Schoretsanitis, G., Neuner, I., Haen, E., Gaebler, A. J., & Paulzen, M. (2023). Discovering interactions in augmentation strategies: Impact of duloxetine on the metabolism of aripiprazole. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.13875
Vancouver
Margraff T, Schoretsanitis G, Neuner I, Haen E, Gaebler AJ, Paulzen M. Discovering interactions in augmentation strategies: Impact of duloxetine on the metabolism of aripiprazole. Basic & Clinical Pharmacology & Toxicology. 2023. doi:10.1111/bcpt.13875
BibTeX
@article{Margraff2023,
author = {Margraff, Teresa and Schoretsanitis, Georgios and Neuner, Irene and Haen, Ekkehard and Gaebler, Arnim Johannes and Paulzen, Michael},
title = {Discovering interactions in augmentation strategies: Impact of duloxetine on the metabolism of aripiprazole},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2023},
doi = {10.1111/bcpt.13875}
}
EUVIMED